Arvinas, Inc. (NASDAQ:ARVN) Q1 Earnings Beat, Revenue Miss, and Major FDA Approval

• Arvinas, Inc. (NASDAQ:ARVN) reported a Q1 2026 earnings beat with an EPS of -$0.90, surpassing analyst estimates, despite missing revenue targets.
• The biotechnology firm achieved a significant milestone with FDA approval for its drug VEPPANU™ for advanced breast cancer, leading to a licensing deal with Rigel Pharmaceuticals.
• Despite current unprofitability indicated by a negative P/E ratio of -2.73, Arvinas demonstrates strong financial health with a low Debt-to-Equity ratio of 0.02 and a robust Current Ratio of 5.44.

Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that creates new therapies to treat diseases using protein degradation. On May 12, 2026, the company reported its first-quarter financial results. The report showed that while Arvinas beat earnings estimates, it missed its revenue targets for the quarter.

The company announced an earnings per share (EPS) of -$0.90, which was better than the analyst consensus estimate of -$0.95. As highlighted by Zacks, this result is a significant drop from the same period a year ago. In that quarter, the company posted positive earnings of $1.14 per share.

For the quarter, Arvinas reported revenues of $15.6 million, which did not meet the estimated $16.61 million. This revenue figure is a substantial decrease from the $188.8 million reported in the year-ago quarter. Over the last four quarters, the company has only managed to beat revenue estimates one time.

Despite the revenue miss, Arvinas announced a major corporate achievement. As reported by GlobeNewswire, the FDA approved its drug VEPPANU™ for treating advanced breast cancer. Following this, Arvinas and its partner Pfizer granted Rigel Pharmaceuticals exclusive global rights to the drug for an $85 million upfront payment and future milestone payments.

Current financial data shows Arvinas has a negative Price-to-Earnings (P/E) ratio of -2.73, which means the company is not currently profitable. However, its financial health appears strong. It has a very low Debt-to-Equity ratio of 0.02 and a Current Ratio of 5.44, indicating it can easily cover its short-term obligations.